A previously healthy 74-year-old man presented with symptoms of heart failure over the last 10 months. Initial tests revealed raised levels of brain natriuretic peptide (617 pg/mL) and a low-voltage ECG. An echocardiogram showed symmetric left ventricular (LV) hypertrophy, systolic dysfunction (ejection fraction 35%; figure 1A , video 1), restrictive filling pattern and decreased global longitudinal strain (figure 1B). As the cardiomyopathy aetiology was unclear, he underwent further testing. A cardiac MRI demonstrated diffuse subendocardial delayed myocardial enhancement after gadolinium injection ( figure 1C ) and amyloid deposits were found on endomyocardial biopsy ( figure 1D ). The serum κ/λ free-light chains (FLC) ratio was 2.4 (increased) and a bone marrow biopsy ruled out multiple myeloma. The final diagnosis was cardiac amyloid light-chain (AL) amyloidosis and he was started on cyclophosphamide, thalidomide and dexamethasone. His congestive symptoms improved with diuretics. At 15 months of follow-up, he is in New York Heart Association class II. 
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DESCRIPTION
A previously healthy 74-year-old man presented with symptoms of heart failure over the last 10 months. Initial tests revealed raised levels of brain natriuretic peptide (617 pg/mL) and a low-voltage ECG. An echocardiogram showed symmetric left ventricular (LV) hypertrophy, systolic dysfunction (ejection fraction 35%; figure 1A , video 1), restrictive filling pattern and decreased global longitudinal strain (figure 1B). As the cardiomyopathy aetiology was unclear, he underwent further testing. A cardiac MRI demonstrated diffuse subendocardial delayed myocardial enhancement after gadolinium injection ( figure 1C ) and amyloid deposits were found on endomyocardial biopsy ( figure 1D ). The serum κ/λ free-light chains (FLC) ratio was 2.4 (increased) and a bone marrow biopsy ruled out multiple myeloma. The final diagnosis was cardiac amyloid light-chain (AL) amyloidosis and he was started on cyclophosphamide, thalidomide and dexamethasone. His congestive symptoms improved with diuretics. At 15 months of follow-up, he is in New York Heart Association class II. Only 5% of patients with unexplained cardiomyopathy are found to have amyloidosis. 1 Amyloid infiltration of the heart results in increased LV thickening seen on echocardiography (associated with reduced ECG voltage). 2 As this finding is indistinguishable from other causes of LV hypertrophy, the use of more advanced imaging techniques such as speckle-tracking echocardiography and cardiac MRI can provide non-invasive evidence suggestive of amyloid cardiomyopathy. 3 However, the diagnosis of cardiac amyloidosis is only confirmed when the biopsy specimen stains with Congo red. In AL amyloidosis, λ or κ FLC is also detectable in serum or urine. Finally, the treatment involves the use of chemotherapy and/or autologous stem cell transplantation.
Learning points ▸ Cardiac amyloidosis should always be considered in patients without hypertension with left ventricle hypertrophy and low-voltage ECG. ▸ Cardiac MRI provides strongly suggestive evidence of amyloid cardiomyopathy. 
